FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200008052> ?p ?o ?g. }

• W3200008052 abstract "Pregnancy-induced changes in plasma pharmacokinetics of many antiretrovirals (ARV) are well-established. Current knowledge about the extent of ARV exposure in lymphoid tissues of pregnant women and within the fetal compartment is limited due to their inaccessibility. Subtherapeutic ARV concentrations in HIV reservoirs like lymphoid tissues during pregnancy may constitute a barrier to adequate virological suppression and increase the risk of mother-to-child transmission (MTCT). The present study describes the pharmacokinetics of three ARVs (efavirenz, dolutegravir, and rilpivirine) in lymphoid tissues and fetal plasma during pregnancy using materno-fetal physiologically-based pharmacokinetic models (m-f-PBPK). Lymphatic and fetal compartments were integrated into our previously validated adult PBPK model. Physiological and drug disposition processes were described using ordinary differential equations. For each drug, virtual pregnant women (n = 50 per simulation) received the standard dose during the third trimester. Essential pharmacokinetic parameters, including Cmax, Cmin, and AUC (0-24), were computed from the concentration-time data at steady state for lymph and fetal plasma. Models were qualified by comparison of predictions with published clinical data, the acceptance threshold being an absolute average fold-error (AAFE) within 2.0. AAFE for all model predictions was within 1.08-1.99 for all three drugs. Maternal lymph concentration 24 h after dose exceeded the reported minimum effective concentration (MEC) for efavirenz (11,514 vs. 800 ng/ml) and rilpivirine (118.8 vs. 50 ng/ml), but was substantially lower for dolutegravir (16.96 vs. 300 ng/ml). In addition, predicted maternal lymph-to-plasma AUC ratios vary considerably (6.431-efavirenz, 0.016-dolutegravir, 1.717-rilpivirine). Furthermore, fetal plasma-to-maternal plasma AUC ratios were 0.59 for efavirenz, 0.78 for dolutegravir, and 0.57 for rilpivirine. Compared with rilpivirine (0 h), longer dose forgiveness was observed for dolutegravir in fetal plasma (42 h), and for efavirenz in maternal lymph (12 h). The predicted low lymphoid tissue penetration of dolutegravir appears to be significantly offset by its extended dose forgiveness and adequate fetal compartment exposure. Hence, it is unlikely to be a predictor of maternal virological failure or MTCT risks. Predictions from our m-f-PBPK models align with recommendations of no dose adjustment despite moderate changes in exposure during pregnancy for these drugs. This is an important new application of PBPK modeling to evaluate the adequacy of drug exposure in otherwise inaccessible compartments." @default.
• W3200008052 created "2021-09-27" @default.
• W3200008052 creator A5037090118 @default.
• W3200008052 creator A5046884271 @default.
• W3200008052 creator A5050656496 @default.
• W3200008052 creator A5056485527 @default.
• W3200008052 creator A5074982429 @default.
• W3200008052 date "2021-09-20" @default.
• W3200008052 modified "2023-10-18" @default.
• W3200008052 title "Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester" @default.
• W3200008052 cites W1501551071 @default.
• W3200008052 cites W1509358020 @default.
• W3200008052 cites W1528461472 @default.
• W3200008052 cites W1607895158 @default.
• W3200008052 cites W1964870005 @default.
• W3200008052 cites W1965266980 @default.
• W3200008052 cites W1967035954 @default.
• W3200008052 cites W1969274526 @default.
• W3200008052 cites W1969899610 @default.
• W3200008052 cites W1977335049 @default.
• W3200008052 cites W1979728686 @default.
• W3200008052 cites W1984105526 @default.
• W3200008052 cites W1988442464 @default.
• W3200008052 cites W2009515164 @default.
• W3200008052 cites W2022258204 @default.
• W3200008052 cites W2029589529 @default.
• W3200008052 cites W2036891300 @default.
• W3200008052 cites W2040200721 @default.
• W3200008052 cites W2051475886 @default.
• W3200008052 cites W2057441748 @default.
• W3200008052 cites W2064140898 @default.
• W3200008052 cites W2071954690 @default.
• W3200008052 cites W2074509263 @default.
• W3200008052 cites W2075135942 @default.
• W3200008052 cites W2082883722 @default.
• W3200008052 cites W2092973631 @default.
• W3200008052 cites W2098096941 @default.
• W3200008052 cites W2101807625 @default.
• W3200008052 cites W2106051882 @default.
• W3200008052 cites W2106408660 @default.
• W3200008052 cites W2110885633 @default.
• W3200008052 cites W2111757787 @default.
• W3200008052 cites W2113497618 @default.
• W3200008052 cites W2114152260 @default.
• W3200008052 cites W2124039449 @default.
• W3200008052 cites W2137868500 @default.
• W3200008052 cites W2151758275 @default.
• W3200008052 cites W2158847005 @default.
• W3200008052 cites W2225273737 @default.
• W3200008052 cites W2246644850 @default.
• W3200008052 cites W2252542195 @default.
• W3200008052 cites W2314461521 @default.
• W3200008052 cites W2322897460 @default.
• W3200008052 cites W2403555361 @default.
• W3200008052 cites W2439785778 @default.
• W3200008052 cites W2490541401 @default.
• W3200008052 cites W2534344708 @default.
• W3200008052 cites W2541900703 @default.
• W3200008052 cites W2563236667 @default.
• W3200008052 cites W2609863249 @default.
• W3200008052 cites W2613954206 @default.
• W3200008052 cites W2621698528 @default.
• W3200008052 cites W2623786390 @default.
• W3200008052 cites W2738721038 @default.
• W3200008052 cites W2762486448 @default.
• W3200008052 cites W2773600267 @default.
• W3200008052 cites W2773669447 @default.
• W3200008052 cites W2783109873 @default.
• W3200008052 cites W2786157050 @default.
• W3200008052 cites W2787130291 @default.
• W3200008052 cites W2886383600 @default.
• W3200008052 cites W2894846477 @default.
• W3200008052 cites W2904966271 @default.
• W3200008052 cites W2954992878 @default.
• W3200008052 cites W2963347187 @default.
• W3200008052 cites W2972966250 @default.
• W3200008052 cites W2996365003 @default.
• W3200008052 cites W3008659839 @default.
• W3200008052 cites W3030343133 @default.
• W3200008052 cites W4243147561 @default.
• W3200008052 cites W4249249019 @default.
• W3200008052 cites W4256447364 @default.
• W3200008052 cites W4291181444 @default.
• W3200008052 cites W161540850 @default.
• W3200008052 doi "https://doi.org/10.3389/fped.2021.734122" @default.
• W3200008052 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8488224" @default.
• W3200008052 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34616699" @default.
• W3200008052 hasPublicationYear "2021" @default.
• W3200008052 type Work @default.
• W3200008052 sameAs 3200008052 @default.
• W3200008052 citedByCount "3" @default.
• W3200008052 countsByYear W32000080522022 @default.
• W3200008052 crossrefType "journal-article" @default.
• W3200008052 hasAuthorship W3200008052A5037090118 @default.
• W3200008052 hasAuthorship W3200008052A5046884271 @default.
• W3200008052 hasAuthorship W3200008052A5050656496 @default.
• W3200008052 hasAuthorship W3200008052A5056485527 @default.
• W3200008052 hasAuthorship W3200008052A5074982429 @default.
• W3200008052 hasBestOaLocation W32000080521 @default.
• W3200008052 hasConcept C112705442 @default.

• next